SCGN and renal carcinoma: The consistent deregulated expression of SCGN leads to the proposition that SCGN could be considered a potential biomarker for certain cancers, such as prostate, large cell neuroendocrine, pituitary, colorectal, and renal cancers (10, 11, 14, 15, 16, 17, 18).